🎉 M&A multiples are live!
Check it out!

Pharmicell Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pharmicell and similar public comparables like Cynata Therapeutics, Aroa Biosurgery, and Mesoblast.

Pharmicell Overview

About Pharmicell

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.


Founded

1968

HQ

South Korea
Employees

n/a

Website

pharmicell.com

Financials

LTM Revenue $46.4M

LTM EBITDA $5.7M

EV

$435M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Pharmicell Financials

Pharmicell has a last 12-month revenue (LTM) of $46.4M and a last 12-month EBITDA of $5.7M.

In the most recent fiscal year, Pharmicell achieved revenue of $46.3M and an EBITDA of $6.7M.

Pharmicell expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Pharmicell valuation multiples based on analyst estimates

Pharmicell P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $46.4M XXX $46.3M XXX XXX XXX
Gross Profit $15.0M XXX $15.2M XXX XXX XXX
Gross Margin 32% XXX 33% XXX XXX XXX
EBITDA $5.7M XXX $6.7M XXX XXX XXX
EBITDA Margin 12% XXX 15% XXX XXX XXX
EBIT $3.6M XXX $3.3M XXX XXX XXX
EBIT Margin 8% XXX 7% XXX XXX XXX
Net Profit $5.0M XXX $4.5M XXX XXX XXX
Net Margin 11% XXX 10% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Pharmicell Stock Performance

As of September 3, 2025, Pharmicell's stock price is KRW 10550 (or $8).

Pharmicell has current market cap of KRW 633B (or $452M), and EV of KRW 610B (or $435M).

See Pharmicell trading valuation data

Pharmicell Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$435M $452M XXX XXX XXX XXX $0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Pharmicell Valuation Multiples

As of September 3, 2025, Pharmicell has market cap of $452M and EV of $435M.

Pharmicell's trades at 9.4x EV/Revenue multiple, and 64.7x EV/EBITDA.

Equity research analysts estimate Pharmicell's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Pharmicell has a P/E ratio of 90.4x.

See valuation multiples for Pharmicell and 15K+ public comps

Pharmicell Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $452M XXX $452M XXX XXX XXX
EV (current) $435M XXX $435M XXX XXX XXX
EV/Revenue 9.4x XXX 9.4x XXX XXX XXX
EV/EBITDA 76.2x XXX 64.7x XXX XXX XXX
EV/EBIT 122.0x XXX 131.0x XXX XXX XXX
EV/Gross Profit 29.0x XXX n/a XXX XXX XXX
P/E 90.4x XXX 100.0x XXX XXX XXX
EV/FCF -152.5x XXX -726.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Pharmicell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Pharmicell Margins & Growth Rates

Pharmicell's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Pharmicell's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pharmicell's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Pharmicell and other 15K+ public comps

Pharmicell Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin 12% XXX 15% XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX n/a XXX XXX XXX
S&M Expenses to Revenue XXX XXX 2% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 12% XXX XXX XXX
Opex to Revenue XXX XXX 26% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Pharmicell Public Comps

See public comps and valuation multiples for Regenerative Medicine and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Pharmicell M&A and Investment Activity

Pharmicell acquired  XXX companies to date.

Last acquisition by Pharmicell was  XXXXXXXX, XXXXX XXXXX XXXXXX . Pharmicell acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Pharmicell

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About Pharmicell

When was Pharmicell founded? Pharmicell was founded in 1968.
Where is Pharmicell headquartered? Pharmicell is headquartered in South Korea.
Who is the CEO of Pharmicell? Pharmicell's CEO is Mr. Hyun-soo Kim.
Is Pharmicell publicy listed? Yes, Pharmicell is a public company listed on KRX.
What is the stock symbol of Pharmicell? Pharmicell trades under 005690 ticker.
When did Pharmicell go public? Pharmicell went public in 1988.
Who are competitors of Pharmicell? Similar companies to Pharmicell include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of Pharmicell? Pharmicell's current market cap is $452M
What is the current revenue of Pharmicell? Pharmicell's last 12 months revenue is $46.4M.
What is the current EV/Revenue multiple of Pharmicell? Current revenue multiple of Pharmicell is 9.4x.
Is Pharmicell profitable? Yes, Pharmicell is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Pharmicell? Pharmicell's last 12 months EBITDA is $5.7M.
What is Pharmicell's EBITDA margin? Pharmicell's last 12 months EBITDA margin is 12%.
What is the current EV/EBITDA multiple of Pharmicell? Current EBITDA multiple of Pharmicell is 76.2x.
What is the current FCF of Pharmicell? Pharmicell's last 12 months FCF is -$2.9M.
What is Pharmicell's FCF margin? Pharmicell's last 12 months FCF margin is -6%.
What is the current EV/FCF multiple of Pharmicell? Current FCF multiple of Pharmicell is -152.5x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.